IL-13
Interleukin-13 (IL-13) is a type 2 cytokine primarily produced by Th2 cells, regulating immune responses through modulation of macrophage and epithelial cell activity[1]. Mechanistically, IL-13 signals via the IL-4 receptor alpha (IL-4Rα)/IL-13Rα1 heterodimer, activating the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, particularly STAT6, to induce gene expression associated with allergic inflammation and tissue remodeling[2][3]. In disease models such as experimental autoimmune encephalomyelitis (EAE), IL-13 exerts anti-inflammatory effects by suppressing Th1 and Th17-mediated neuroinflammation, highlighting its role in immune regulation and potential neuroprotective function[4][5]. Compared with related isoforms like IL-4, IL-13 demonstrates distinct receptor-binding affinities and downstream signaling kinetics, which influence the magnitude and specificity of cellular responses[6]. Pharmacological agonists of IL-13 or IL-13R pathways have been employed experimentally to modulate immune cell polarization and cytokine production, whereas IL-13 neutralizing antibodies are utilized to dissect isoform-specific effects in inflammatory models[1][6]. These experimental applications provide insight into IL-13’s selective regulation of immune pathways, offering mechanistic understanding and design considerations for cytokine-targeted interventions in autoimmune and allergic diseases[2].
References:
- [1]. Mannie MD, et al. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol. 2012 Aug 20;3:255. [Content Brief]
- [2]. Liu Y, et al. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol. 2014 Jan 1;192(1):59-72. [Content Brief]
- [3]. Benveniste EN, et al. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res. 2014 Aug;34(8):577-88. [Content Brief]
- [4]. Peón AN, et al. Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive Microenvironment. Mediators Inflamm. 2017;2017:8494572. [Content Brief]
- [5]. Johnson BM, et al. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways. J Immunol. 2021 May 1;206(9):2015-2028. [Content Brief]
- [6]. Vandenbroeck K, et al. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol. 2004 Feb;56(2):145-60. [Content Brief]
-
IL-13 Related Products (51)
Related Products (51)
-
Recombinant Proteins (19)
-
Anti-CD1a Antibody (OKT-6)
0 ImagesCat. No.: HY-P990869Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonal antibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977).
-
APH003
0 ImagesCat. No.: HY-184915CAS No.: 3065495-08-8APH003 is an orally active IRAK4 PROTAC degrader with a DC50 of 0.74 nM in human peripheral blood mononuclear cells (hPBMCs). APH003 recruits IRAK4 to CRBN to form a ternary complex, mediates the ubiquitination and degradation of IRAK4 via the ubiquitin-proteasome pathway, and inhibits the kinase activity of IRAK4. APH003 inhibits LPS- or IL-1β/LPS-induced phosphorylation of ERK, JNK and NF-κB. APH003 inhibits the secretion of TNF-α, IL-6, IL-8 and IL-13 by stimulated hPBMCs. APH003 exhibits anti-inflammatory activity in rat TNBS-induced intestinal inflammation models and mouse IL-33-induced skin inflammation models. APH003 can be used in research related to inflammatory bowel disease and skin inflammation.
-
DOTA-Pep-1L
0 ImagesCat. No.: HY-P11287DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research.
-
MEDI-7836
0 ImagesCat. No.: HY-P991259MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases.
-
PDE4-IN-8
0 ImagesCat. No.: HY-144684CAS No.: 2415085-45-7PDE4-IN-8 (Example 5) is a potent PDE4 inhibitor with an IC50 of 0.93 nM for PDE4B2.PDE4-IN-8 has little effect on IL13 (IC50=4.04 nM), IL4 (IC50=36.33 nM), IFNy (IC50=2394 nM).
-
AVP-13358
0 ImagesCat. No.: HY-165484CAS No.: 459805-03-9AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses.
-
GNE-7056
0 ImagesCat. No.: HY-189477CAS No.: 1557236-81-3GNE-7056 is an orally active interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.2 nM against human kinase, and exhibits high selectivity over LCK kinase. GNE-7056 inhibits PLCγ-1 phosphorylation, suppresses the production of IL-2, IL-4, IL-13 and TH2 cytokines, reduces CD4+ T-cell proliferation, and inhibits activation-induced cell death of CD4+ T cells by decreasing the abundance of FasL. GNE-7056 can be used in asthma-related research.
-
CSL-360
0 ImagesCat. No.: HY-P991648CSL-360 is a chimeric unconjugated IgG1 monoclonal antibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research.
-
Anti-inflammatory agent 89
0 ImagesCat. No.: HY-161815Anti-inflammatory agent 89 is a multi-target glucocorticoid-isothiocyanate hybrid with anti-inflammatory activity. Anti-inflammatory agent 89 releases hydrogen sulfide via its isothiocyanate group, inhibits antigen-induced mast cell degranulation, alleviates pulmonary inflammation, and suppresses bronchial hyperresponsiveness and airway fibrosis. Anti-inflammatory agent 89 can be used in asthma research.
-
ANB032
0 ImagesCat. No.: HY-P992182ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].
-
Aloin (mixture of A&B) (Standard)
0 ImagesAloin (mixture of A&B) (Standard) is the analytical standard of Aloin (mixture of A&B) (HY-N6013). This product is intended for research and analytical applications. Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma.
